The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2022 | Determining the optimal threshold to test MRD in multiple myeloma
In this video, Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL, discusses the optimal threshold for testing measurable residual disease (MRD) in patients with multiple myeloma. Although it has been agreed that 10^-5 is an appropriate threshold, Dr Landgren explains the value of using more sensitive tools at a threshold of 10^-6, and incorporating blood-based assays in clinical practice. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Janssen: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials, Research Funding; Amgen: Research Funding; Merck: Consultancy, Other: Independent Data Monitoring Committee (IDMC) member for clinical trials; Pfizer: Consultancy.
